{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Part+B&page=5", "query": { "intervention": "Part B", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 2262, "total_pages": 227, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Part+B&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Part+B&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-20T13:22:39.273Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05938036", "title": "Study of Safety and Efficacy of ALT-100mAb in Participants With Moderate/Severe ARDS", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Respiratory Distress Syndrome (ARDS)" ], "interventions": [ { "name": "ALT-100 mAb", "type": "DRUG" }, { "name": "ALT-100 (Placebo)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Aqualung Therapeutics Corp.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 15, "start_date": "2023-12-01", "completion_date": "2027-07-01", "has_results": false, "last_update_posted_date": "2025-10-23", "last_synced_at": "2026-10-20T13:22:39.273Z", "location_count": 1, "location_summary": "Tucson, Arizona", "locations": [ { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT05938036" }, { "nct_id": "NCT04304144", "title": "A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "AL Amyloidosis" ], "interventions": [ { "name": "CAEL-101", "type": "DRUG" }, { "name": "SoC: cyclophosphamide, bortezomib, and Dexamethasone (CyBorD)", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alexion Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 25, "start_date": "2020-03-18", "completion_date": "2023-11-14", "has_results": true, "last_update_posted_date": "2025-03-05", "last_synced_at": "2026-10-20T13:22:39.273Z", "location_count": 3, "location_summary": "Stanford, California • Detroit, Michigan • Cleveland, Ohio", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04304144" }, { "nct_id": "NCT03220204", "title": "Researching Emotions And Cardiac Health: Phase III", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Congestive Heart Failure", "Emotions", "Patient Compliance" ], "interventions": [ { "name": "PP-based health behavior intervention", "type": "BEHAVIORAL" }, { "name": "MI-based educational control condition", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2017-09-01", "completion_date": "2019-09-09", "has_results": true, "last_update_posted_date": "2021-08-30", "last_synced_at": "2026-10-20T13:22:39.273Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03220204" }, { "nct_id": "NCT06067230", "title": "A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Respiratory Syncytial Virus" ], "interventions": [ { "name": "mRNA-1345", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "ModernaTX, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1153, "start_date": "2023-10-06", "completion_date": "2026-07-24", "has_results": false, "last_update_posted_date": "2026-08-20", "last_synced_at": "2026-10-20T13:22:39.273Z", "location_count": 32, "location_summary": "Glendale, Arizona • Phoenix, Arizona • Tempe, Arizona + 28 more", "locations": [ { "city": "Glendale", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06067230" }, { "nct_id": "NCT06185751", "title": "Safety and Efficacy of CS1 CAR-T (WS-CART-CS1) in Subjects With Multiple Myeloma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "WS-CART-CS1", "type": "BIOLOGICAL" }, { "name": "Lymphodepleting chemotherapy", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2024-08-22", "completion_date": "2040-08-31", "has_results": false, "last_update_posted_date": "2026-07-09", "last_synced_at": "2026-10-20T13:22:39.273Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT06185751" }, { "nct_id": "NCT02082977", "title": "A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Transformed Follicular Lymphoma, Other Non-Hodgkin's Lymphomas, Solid Tumors and Multiple Myeloma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer", "Neoplasms" ], "interventions": [ { "name": "GSK2816126", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2014-04-24", "completion_date": "2017-06-20", "has_results": true, "last_update_posted_date": "2020-02-25", "last_synced_at": "2026-10-20T13:22:39.273Z", "location_count": 2, "location_summary": "Chicago, Illinois • New York, New York", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02082977" }, { "nct_id": "NCT06698575", "title": "A Study to Assess the Safety, Pharmacokinetics, and Tolerability of ABI-1179 in Healthy Subjects and in Subjects Seropositive for HSV-2 With Recurrent Genital Herpes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Genital Herpes Simplex Type 2" ], "interventions": [ { "name": "ABI-1179", "type": "DRUG" }, { "name": "ABI-1179 Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Assembly Biosciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 103, "start_date": "2024-12-08", "completion_date": "2026-01-19", "has_results": false, "last_update_posted_date": "2026-03-23", "last_synced_at": "2026-10-20T13:22:39.273Z", "location_count": 4, "location_summary": "Kansas City, Missouri • Rochester, New York • Seattle, Washington", "locations": [ { "city": "Kansas City", "state": "Missouri" }, { "city": "Rochester", "state": "New York" }, { "city": "Seattle", "state": "Washington" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT06698575" }, { "nct_id": "NCT05574010", "title": "A Study of Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of KAN-101 in Celiac Disease (ACeD-it)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Celiac Disease" ], "interventions": [ { "name": "Cohort 1 in Part A", "type": "DRUG" }, { "name": "Cohort 2 in Part A", "type": "DRUG" }, { "name": "Placebo: Group 1 in Part B and Part C", "type": "OTHER" }, { "name": "Group 2 in Part B and Part C", "type": "DRUG" }, { "name": "Group 3 in Part B and Part C", "type": "DRUG" }, { "name": "Group 4 in Part B and Part C", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 128, "start_date": "2022-11-15", "completion_date": "2025-05-19", "has_results": true, "last_update_posted_date": "2026-03-10", "last_synced_at": "2026-10-20T13:22:39.273Z", "location_count": 23, "location_summary": "Birmingham, Alabama • Anaheim, California • St. Petersburg, Florida + 20 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anaheim", "state": "California" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "Sandy Springs", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05574010" }, { "nct_id": "NCT06953960", "title": "A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Surzetoclax", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Etentamig", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 325, "start_date": "2025-07-23", "completion_date": "2030-12", "has_results": false, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-10-20T13:22:39.273Z", "location_count": 12, "location_summary": "Los Angeles, California • New Haven, Connecticut • Boston, Massachusetts + 9 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06953960" }, { "nct_id": "NCT05623020", "title": "A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Elranatamab", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1060, "start_date": "2022-11-10", "completion_date": "2033-10-03", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-20T13:22:39.273Z", "location_count": 17, "location_summary": "Jupiter, Florida • Lincoln, Nebraska • Reno, Nevada + 10 more", "locations": [ { "city": "Jupiter", "state": "Florida" }, { "city": "Lincoln", "state": "Nebraska" }, { "city": "Reno", "state": "Nevada" }, { "city": "Reno", "state": "Nevada" }, { "city": "Reno", "state": "Nevada" } ], "official_url": "https://clinicaltrials.gov/study/NCT05623020" } ] }